PTK2 and hepatocellular carcinoma: Chang et al. showed that Dasatinib inhibited the SFK/FAK and PI3K/PTEN/Akt pathways by down-regulating the Src tyrosine kinase, thus preventing the adhesion, proliferation, invasion, and migration of HCC cells in vitro [60].